natgillin/translations-raw huggingface dataset:
For very small and small dogs, squeeze pipette firmly applying the entire contents directly to the skin in one spot, between the shoulder blades.
Za zelo majhne in majhne pse merilno kapalko dobro stisnite, da nanesete vso vsebino neposredno na kožo na enem mestu med lopaticama.
for very small dogs (2– 4.5 kg)
za zelo majne pse 2-4,5 kg
for very small dogs (2–4.5 kg)
za zelo majhne pse (2-4,5 kg)
for very small dogs 2 – 4.5 kg
za zelo majne pse 2-4,5 kg
For viral safety see section 4.4
Za varnost pred virusi glejte poglavje 4.4.
For waiting times for re-administration of rocuronium or vecuronium after reversal with sugammadex, see section 4.4.
Za časovne presledke pred ponovno uporabo rokuronija ali vekuronija po prekinitvi blokade s sugamadeksom glejte poglavje 4.4.
For weight, pre-treatment to end of long-term follow-up, weight- for-age percentiles decreased 1.3 and 5.5 percentiles among subjects treated for 24 weeks or 48 weeks, respectively.
Za telesno maso se je percentil telesne mase za starost od časa pred zdravljenjem do konca dolgoročnega spremljanja preiskovancem, zdravljenim 24 tednov, zmanjšal za 1,3 percentila in preiskovancem, zdravljenim 48 tednov, za 5,5 percentila.
For wet AMD and macular oedema, three or more consecutive monthly injections may be needed initially.
Pri vlažni obliki starostne degeneracije makule in makularnem edemu bodo morda na začetku potrebne tri injekcije ali več zapored na mesec.
For wet AMD, one injection of 2 mg is given into the affected eye every month for three consecutive months, followed by one injection every two months.
Pri vlažni obliki starostne degeneracije makule se v prizadeto oko prve tri mesece daje ena injekcija v odmerku 2 mg enkrat mesečno, čemur sledi ena injekcija vsaka dva meseca.
For white high-density polyethylene bottles, use within 30 days after the first opening
Vsebino belih plastenk iz polietilena visoke gostote porabite v 30 dneh po prvem odprtju.
For whole herd vaccination, an injection of one dose may be administered per gilt, sow and boar every 4 months.
Za cepljenje cele črede se priporoča injicirati po en odmerek na mladico, svinjo in merjasca vsake 4 mesece.
For WNV lineage 2 strains the duration of immunity has not been established.
Za VWN linije 2 trajanja imunosti niso določili.
For women aged 50 to 54 years taking 5 years of HRT, this results in about 1 extra case per 2,000 users.
Pri ženskah, starih od 50 do 54 let, ki uporabljajo HNZ 5 let, to povzroča približno en dodaten primer na 2.000 uporabnic.
FOR WOMEN OF CHILD BEARING AGE
ZA ŽENSKE V RODNI DOBI
For women of child-bearing potential
za ženske v rodni dobi
For women of child-bearing potential a negative pregnancy test should be confirmed before starting treatment;
ženske v rodni dobi morajo pred začetkom zdravljenja opraviti test nosečnosti, ki mora
For women of childbearing potential
Za ženske v rodni dobi
For women of childbearing potential, prescriptions of Thalidomide Celgene should be limited to 4 weeks of treatment and continuation of treatment requires a new prescription.
Pri ženskah v rodni dobi je treba predpisovanje zdravila Thalidomide Celgene omejiti na 4 tedne zdravljenja, za nadaljevanje zdravljenja pa je treba izdati nov recept.
For women receiving teriflunomide treatment, who wish to become pregnant, the medicine should be stopped and an accelerated elimination procedure is recommended in order to more rapidly achieve concentration below 0.02 mg/l (see below):
Če ženska, ki jemlje teriflunomid, želi zanositi, je priporočljiva prekinitev zdravljenja in uvedba postopka pospešenega izločanja, da se hitreje doseže upad koncentracije pod 0,02 mg/l (glejte nadaljevanje):
For women taking Inflectra including those over 60 years of age, your doctor may recommend that you continue to be regularly screened for cervical cancer.
Ženskam, ki prejemajo zdravilo Inflectra, vključno s starejšimi od 60 let, lahko zdravnik priporoči, da nadaljujejo z rednimi presejalnimi testi za raka materničnega vratu.
For women taking infliximab including those over 60 years of age, your doctor may recommend that you continue to be regularly screened for cervical cancer.
Ženskam, ki prejemajo infliksimab, vključno s starejšimi od 60 let, lahko zdravnik priporoči, da nadaljujejo z rednimi presejalnimi testi za raka materničnega vratu.
For women taking Remicade including those over 60 years of age, your doctor may recommend that you continue to be regularly screened for cervical cancer.
Ženskam, ki prejemajo zdravilo Remicade, vključno s starejšimi od 60 let, lahko zdravnik priporoči, da nadaljujejo z rednimi presejalnimi testi za raka materničnega vratu.
For women taking Remsima including those over 60 years of age, your doctor may recommend that you continue to be regularly screened for cervical cancer.
Ženskam, ki prejemajo zdravilo Remsima, vključno s starejšimi od 60 let, lahko zdravnik priporoči, da nadaljujejo z rednimi presejalnimi testi za raka materničnega vratu.
For women taking Revlimid
Za ženske, ki jemljejo zdravilo Revlimid
For women taking Thalidomide Celgene
Za ženske, ki jemljejo zdravilo Thalidomide Celgene
For women with a history of cholestatic jaundice associated with past oestrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, DUAVIVE should be discontinued.
Pri ženskah s holestatskim ikterusom, povezanim s preteklo uporabo estrogenov ali z nosečnostjo, je potrebna previdnost, pri ponovitvi bolezni pa je treba zdravljenje z zdravilom DUAVIVE prekiniti.
For women with child-bearing potential:
Za ženske v rodni dobi:
For worms, Broadline is used to treat tapeworms and roundworms in the gut as well as a type of worm that infests the bladder and a type of feline lungworm.
Za zdravljenje infestacij s črvi se zdravilo Broadline uporablja za zdravljenje infestacij s trakuljami in valjastimi črvi v črevesju ter vrsto črvov, ki napade sečni mehur, in vrsto mačjega pljučnega črva, za
For you or your child’s safety, the delivery systems intended for administration of INOmax are fitted with devices that constantly measure the amount of nitric oxide, oxygen and nitrogen dioxide (a chemical formed when nitric oxide and oxygen are mixed) being delivered to the lungs.
Za vašo varnost in varnost vašega otroka je sistem za dovajanje zdravila INOmax opremljen z napravami, ki nenehno merijo količino dušikovega oksida, kisika in dušikovega dioksida (kemične snovi, ki se tvori ob mešanju dušikovega oksida in kisika), ki se dovaja v pljuča.
For young infants the contents may be mixed with infant formula, expressed breast milk or fruit puree and for infants and children under 6 years, mixed with soft food such as mashed potatoes or apple puree.immediately.
Pri majhnih dojenčkih se lahko vsebina zmeša z otroško formulo, iztisnjenim materinim mlekom ali sadno kašico, pri dojenčkih in otrocih, mlajših od šest let, pa z mehko hrano, kot je krompirjev pire ali jabolčna čežana.
For younger patients (3 months to 12 years), it is given twice a day, and the dose is based on the weight of the patient (15 mg per kilogram body weight) but must not exceed 1 g per day.
Pri mlajših bolnikih (starih od 3 mesece do 12 let) se zdravilo daje dvakrat dnevno, odmerek pa je odvisen od telesne mase bolnika (15 mg na kilogram telesne mase), pri čemer ne sme biti večji od 1 g dnevno.
For younger patients, the recommended dose depends on the body surface area (calculated using the patient’s height and weight).
Pri mlajših bolnikih je priporočeni odmerek odvisen od telesne površine (izračunane glede na telesno višino in maso bolnika).
For your child’s best protection, it is necessary to take the doctor’s advice about when to return for additional doses of Synagis.
Za najboljšo zaščito vašega otroka upoštevajte zdravnikova navodila o tem, kdaj je treba priti po dodatne odmerke zdravila Synagis.
For your first 2 infusions, your doctor or nurse will monitor you closely during the infusion and for approximately 2 hours after you have completed the infusion.
Pri prvih dveh infuzijah zdravila vas bo zdravnik ali medicinska sestra skrbno nadziral(-a) med infundiranjem in še približno 2 uri po končanem infundiranju zdravila.
For your first injection go directly to Section 3 - Step C.
Za prvo injiciranje pojdite naravnost na 3. poglavje – korak C.
For your first injection go directly to Section 3 – Step C.
Za prvo injiciranje pojdite naravnost na 3. poglavje – korak C.
For your next dose, be sure to firmly push and hold the injection button in and slowly count to 5 before removing needle from skin.
Pri naslednjem odmerjanju zagotovite, da boste gumb za injiciranje čvrsto pritisnili in držali ter počasi šteli do 5, preden boste iz kože izvlekli iglo.
For your next injection you can return to your chosen injection day.
Za vašo naslednjo injekcijo se lahko vrnete k prvotno izbranem dnevu.
For ½ scoop:
Za ½ merico:
FORCALTONIN 100 IU solution for injection
FORCALTONIN 100 IE raztopina za injiciranje
FORCALTONIN 100 IU solution for injection Recombinant salmon calcitonin
FORCALTONIN 100 IE raztopina za injiciranje Rekombinanten lososov kalcitonin
FORCALTONIN 100 IU solution for injection Recombinant salmon calcitonin
FORCALTONIN 100 IE raztopina za injiciranje Rekombinanten lososov kalcitonin.
Forcaltonin is given by subcutaneous injection (under the skin), intramuscular injection (into a muscle) or intravenous infusion (drip into a vein – only in hypercalcaemia).
Zdravilo Forcaltonin se daje s subkutano (podkožno) injekcijo, intramuskularno injekcijo (v mišico) ali z intravensko infuzijo (dajanje v veno – le pri hiperkalciemiji).
Forced expiratory volume decreased
zmanjšanje forsiranega ekspiratornega volumna
Forced expiratory volume decreased*
mase**, zmanjšanje forsiranega ekspiratornega volumna
Forced expiratory volume decreased1 Chest pain1
ekspiracijski volumen1 bolečine v prsnem košu1 draženje žrela1
Forced Vital Capacity (Percent of predicted normal)
forsirana vitalna kapaciteta (odstotek predvidene normalne vrednosti)
Foreign body reactions
Reakcije na tujke
Forest plot for subgroup analysis of overall survival (ITT population)
Drevesni graf analize celokupnega preživetja po podskupinah (populacija z-namenom- zdravljenja)
Forest plot of CR/CRh* rate during the first two cycles for study MT103-211 (primary analysis set)
Gozdni diagram deleža CR/CRh* v prvih dveh ciklusih v študiji MT103-211 (nabor za primarno analizo)
Forget to inject your insulin or stop taking insulin.
i pozabite injicirati insulin ali ga nehate uporabljati,
Forget to inject your insulin or stop taking insulin.
če si pozabite injicirati insulin ali ga nehate uporabljati,
Forget to take your insulin or stop taking insulin.
i pozabite injicirati insulin ali ga nehate uporabljati,
forgetfulness
pozabljivost,
forgetfulness, confusion, fitting (seizures), incoherent speech, tremor (shaking)
pozabljivost, zmedenost, epileptični napadi, nerazumljiv govor, tremor (tresenje);
Form
farmacevtska
Form
infundiranje
Form
nazalna
form
oblika
Form
pakiranja
Form a skin fold by pinching the skin between the thumb and the forefinger.
S palcem in kazalcem napravite kožno gubo.
Form a skin fold by pinching the skin between thumb and forefinger.
S palcem in kazalcem naredite kožno gubo.
Form of lung irritation called interstitial lung disease (uncommon in European patients; common in Japanese patients: may affect up to 1 in 100 people in Europe and up to 1 in 10 in Japan).
Oblika vnetja pljuč, ki se imenuje intersticijska bolezen pljuč (občasna pri evropskih bolnikih: pojavi se lahko pri največ 1 od 100 bolnikov; pogosta pri japonskih bolnikih: pojavi se lahko pri največ 1 od 10 bolnikov).
Formal drug interaction studies have not been performed, but no drug interactions have been described to date, including patients receiving antibiotics.
Uradne študije medsebojnega delovanja z drugimi zdravili niso bile izvedene, vendar do danes ni bila opisana nobena reakcija medsebojnega delovanja z drugimi zdravili, vključno z antibiotiki.
Formal studies have not been conducted to evaluate the pharmacokinetics of Soliris administration in special PNH patient populations based on gender, race, age (geriatric), or renal or hepatic impairment.
Formalne študije za oceno farmakokinetike zdravila Soliris pri posebnih skupinah bolnikov s PNH na podlagi spola, rase, starosti (geriatrične) ali okvare ledvic ali jeter niso bile izvedene.
Formal studies have not been performed in patients with renal or hepatic impairment.
Uradne študije pri bolnikih z okvarjenim delovanjem ledvic in jeter niso bile opravljene.
Formal studies of the potential effect of Ilaris on human fertility have not been conducted.
Formalnih študij možnega vpliva zdravila Ilaris na plodnost pri ljudeh niso izvajali.
formaldehyde neomycin or polymyxin (antibiotics).
formaldehid; neomicin ali polimiksin (antibiotika).
formaldehyde. neomycin or polymyxin (antibiotics).
formaldehid; neomicin ali polimiksin (antibiotika).
Format of the simplified PSUR:
Format za poenostavljeno poročilo PSUR:
Formation of a blood clot in a deep vein (deep vein thrombosis) or blockage of the main artery of the lung or one of its branches (pulmonary embolism), or blockage due to a blood clot elsewhere in the blood stream (embolism)
nastanek krvnega strdka v globoki veni (globoka venska tromboza) ali zapora glavne pljučne arterije ali ene izmed njenih vej (pljučna embolija) ali zapora zaradi krvnega strdka drugje v krvnem obtoku (embolija),
formation of a blood clot inside the penile vein
nastajanje krvnih strdkov znotraj vene penisa
Formation of anti-hirudin antibodies was observed in about 40 % of HIT type II patients and have been reported especially with a treatment period exceeding five days.
Pri 40 % bolnikov s HIT tipa II so opazili tvorbo protiteles proti hirudinu, poročila pa jih omenjajo zlasti v povezavi z zdravljenjem, ki je trajalo dlje kot 5 dni.
formation of blood clots past experience of excessive gambling
krvnih strdkov, če ste kdaj imeli težave s pretiranim hazardiranjem.
formation of blood clots which may be carried off in the blood circulation (thromboembolic reactions) and which may result e.g. in myocardial infarction (e.g. when you have sudden chest pain or shortness of breath), stroke (e.g. when you have a sudden onset of muscle weakness, have loss of sensation and/or balance, decreased alertness or difficulty in speaking), blood clots in the arteries of the lungs (e.g. when you have chest pain, difficulty in breathing or are coughing up blood), deep vein thrombosis (e.g. when you have redness, feel warmth, pain, tenderness, or have a swelling of one or both legs), chest pain, chest discomfort, painful respiration due to transfusion related lung injury (TRALI)
tvorbi krvnih strdkov, ki lahko potujejo po krvnem obtoku (trombembolične reakcije) in lahko npr. povzročijo miokardni infarkt (npr. če občutite nenadno bolečino v prsih ali kratko sapo), možgansko kap (npr. če doživite nenadno mišično oslabelost, izgubo občutenja in/ali ravnotežja, zmanjšano pozornost ali težave z govorjenjem), krvne strdke v pljučnih arterijah (npr. če imate bolečino v prsih, težave z dihanjem ali izkašljujete kri), globoko vensko trombozo (npr. če imate rdečino, občutek toplote, bolečino, občutljivost ali oteklost ene ali obeh nog). bolečina v prsnem košu, občutek neugodja v prsnem košu, boleče dihanje zaradi s transfuzijo povezane akutne okvare pljuč (TRALI).
Formation of methaemoglobin
Nastajanje methemoglobina
formation of stones in the gall bladder
nastanek kamnov v žolčniku
Formation or presence of a blood clot within a blood vessel – vein or artery (thrombosis)
nastanek ali prisotnost krvnega strdka v žili – veni ali arteriji (tromboza)
Former Smokers
Nekdanji kadilci
Formoterol 12 twice a day
formoterol
Formoterol fumarate dihydrate belongs to a group of medicines called ‘long-acting β2 adrenoceptor agonists’ or ‘bronchodilators’.
Formoterolijev fumarat dihidrat spada v skupino zdravil, imenovanih »dolgodelujoči agonisti adrenergičnih receptorjev β2 ali »bronhodilatatorji«.
Formoterol fumarate dihydrate belongs to a group of medicines called ‘long-acting β2 adrenoceptor agonists’ or ‘bronchodilators’.
Formoterolijev fumarat dihidrat spada v skupino zdravil, imenovanih »dolgodelujoči agonisti adrenergičnih receptorjev β2« ali »bronhodilatatorji«.
forms a complex with the neuromuscular blocking agents rocuronium or vecuronium in plasma and thereby reduces the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction.
V plazmi se veže na mišična relaksanta rokuronij ali vekuronij in z njima tvori kompleks ter tako zmanjšuje količino mišičnega relaksanta, ki je na voljo za vezavo na nikotinske receptorje v živčnomišičnem stiku.
forms of hormonal
hormonske kontracepcije
Formulation
Farmacevtska oblika
FORMULATION
PRIPRAVEK
FORMULATION
pro pro
FORMULATION BUFFER SOLUTION VIAL
VIALA Z RAZTOPINO PUFRA ZA PRIPRAVO FORMULACIJE
Formulation buffer vial: Human albumin solution Sodium chloride
Viala s pufrom za pripravo formulacije: raztopina humanega albumina natrijev klorid
formulation) alone)
mehkim gelom)
FORSTEO (rhPTH(1-34)) is the active fragment (1-34) of endogenous human parathyroid hormone.
Zdravilo FORSTEO (rhPTH(1-34)) je aktivni fragment (1-34) endogenega humanega paratiroidnega hormona.
FORSTEO (see
FORSTEO (glejte
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen
FORSTEO 20 mikrogramov/80 mikrolitrov raztopina za injiciranje v napolnjenem injekcijskem peresniku
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen Teriparatide
FORSTEO 20 mikrogramov/80 mikrolitrov raztopina za injiciranje v napolnjenem injekcijskem peresniku teriparatid
Forsteo can be used for up to two years.
Zdravilo Forsteo se lahko jemlje do dve leti.
FORSTEO contains the active substance teriparatide that is used to make the bones stronger, and to reduce the risk of fractures by stimulating bone formation.
Zdravilo FORSTEO vsebuje zdravilno učinkovino teriparatid, ki jo uporabljamo za krepitev kosti in zmanjšanje tveganja za zlome s spodbujanjem tvorjenja kostnine.
FORSTEO has no or negligible influence on the ability to drive and use machines.
Zdravilo FORSTEO nima vpliva ali pa ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
FORSTEO is a colourless and clear solution.
Zdravilo FORSTEO je brezbarvna in bistra raztopina.
FORSTEO is contraindicated for use during pregnancy (see section 4.3).
Zdravilo FORSTEO je med nosečnostjo kontraindicirano (glejte poglavje 4.3).
FORSTEO is eliminated through hepatic and extra-hepatic clearance (approximately 62 L/hr in women and 94 L/hr in men).
Zdravilo FORSTEO se izloča z jetrnim in zunaj-jetrnim očistkom (približno 62 l/h pri ženskah in 94 l/h pri moških).
FORSTEO is indicated in adults.
Zdravilo FORSTEO je indicirano pri odraslih.
FORSTEO is supplied in a pre-filled pen.
Zdravilo FORSTEO je na voljo v napolnjenem injekcijskem peresniku.
Forsteo is used for the treatment of osteoporosis (a disease that makes bones fragile) in the following groups: women who have been through the menopause.
Zdravilo Forsteo se uporablja za zdravljenje osteoporoze (bolezni, ki povzroča krhkost kosti) pri naslednjih skupinah: ženskah po menopavzi.
FORSTEO may cause an increase in the amount of calcium in your blood or urine.
Zdravilo FORSTEO lahko poviša količino kalcija v vaši krvi ali urinu.
Forsteo must not be used in patients who have other bone diseases such as Paget’s disease, bone cancer or bone metastases (cancer that has spread to the bone), patients who have had radiation therapy of the skeleton, or patients who have hypercalcaemia (high blood calcium levels), unexplained high levels of alkaline phosphatase (an enzyme) or severe kidney disease.
Zdravilo Forsteo se ne sme uporabljati pri bolnikih, ki imajo druga obolenja kosti, kot so Pagetova bolezen, kostni rak ali metastaze v kosteh (rak, ki se je razširil na kosti), bolnikih, ki so bili na obsevanju okostja, ali bolnikih, ki imajo hiperkalciemijo (visoke ravni kalcija v krvi), tistih z nepojasnjeno visokimi ravnmi alkalne fosfataze (vrste encima) ali hudim obolenjem ledvic.
FORSTEO should be administered once daily by subcutaneous injection in the thigh or abdomen.
Zdravilo FORSTEO se uporablja enkrat dnevno kot subkutana injekcija v stegno ali trebuh.
FORSTEO should be stored in a refrigerator (2C to 8C) at all times.
Zdravilo FORSTEO vedno shranjujte v hladilniku (2 °C - 8 °C).
FORSTEO should not be used in children and adolescents (less than 18 years).
Zdravila FORSTEO se ne sme uporabljati pri otrocih in mladostnikih (mlajših od 18 let).
Fortacin 150 mg/ml + 50 mg/ml cutaneous spray, solution Lidocaine/Prilocaine
Fortacin 150 mg/50 mg v 1 ml dermalno pršilo, raztopina lidokain/prilokain
Fortacin has no or negligible influence on the ability to drive and use machines.
Zdravilo Fortacin nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Fortacin is a combination of two medicines (lidocaine and prilocaine).
Zdravilo Fortacin je kombinacija dveh zdravil (lidokaina in prilokaina).
Fortacin is not approved for use by women.
Zdravilo Fortacin ni indicirano za uporabo pri ženskah.
Fortacin may also come into contact with other mucous membranes such as your, or your partner’s, mouth, nose and throat, causing them to feel slightly numb for a short while.
Zdravilo Fortacin lahko pride v stik tudi z drugimi sluznicami, na primer ust, nosu in žrela vas ali vaše partnerke, kar za kratek čas povzroči rahlo omrtvelost.
Fortacin may reduce the possibility of pregnancy, but is not a reliable contraceptive.
Zdravilo Fortacin lahko zmanjša možnost zanositve, vendar ni zanesljiv kontraceptiv.
Fortacin sprayed onto mucous membranes of the patient or their partner, such as the mouth, nose and throat, or transferred onto female genitalia or anal lining, could be absorbed and temporary local numbness/anaesthesia is likely to result.
Če se zdravilo Fortacin razprši v sluznice bolnika ali njegove partnerke, na primer ust, nosu ali žrela, ali prenese na ženska spolovila ali analne dele, se lahko absorbira in povzroči začasno lokalno omrtvelost/anestezijo.
FORTEKOR PLUS 1.25 mg/2.5 mg tablets
FORTEKOR PLUS 1,25 mg/2,5 mg
FORTEKOR PLUS is a combination of 2 active substances: pimobendan and benazepril hydrochloride.
FORTEKOR PLUS je kombinacija dveh zdravilnih učinkovin: pimobendana in benazeprilijevega klorida.
FORTEKOR PLUS tablets can be divided into halves if needed.
Tablete FORTEKOR PLUS lahko po potrebi razpolovimo na enaka dela.
Forty (80%) of these patients had an increase in their haemoglobin to within the normal range at week 12, in comparison to 2 out of 29 (7%) of placebo treated patients with haemoglobin at baseline (p<0.0001).
Štiridesetim (80 %) od teh bolnikov se je hemoglobin na vrednost znotraj normale zvišal do 12. tedna v primerjavi z 2 od 29 (7 %) bolnikov, ki so prejemali placebo in ki so imeli pred začetkom zdravljenja hemoglobin pod spodnjo mejo normale (p < 0,0001).
Forty eight percent (48.1%, 39/81) of the patients treated with placebo flared compared with 25.6% (21/82) of tocilizumab treated patients.
Do nenadnega poslabšanja bolezni je prišlo pri 48,1 % (39/81) bolnikih, ki so se zdravili s placebom, v primerjavi s 25,6 % (21/82) bolnikov, ki so se zdravili s tocilizumabom.
Forty four percent of patients in the fluticasone furoate/vilanterol 92/22 group were well controlled (ACQ7 ≤0.75) at end of treatment compared to 36% of subjects in the FF 92 micrograms group (p<0.001 95% CI 1.23, 1.82).
44 % bolnikov v skupini s flutikazonfuroatom/vilanterolom 92/22 mikrogramov je imelo na koncu zdravljenja dobro obvladano bolezen (ACQ7 ≤ 0,75); v skupini z 92 mikrogrami FF je bilo takšnih 36 % (p < 0,001, 95 % IZ od 1,23 do 1,82).
Forty four percent of patients in the fluticasone furoate/vilanterol 92/22 micrograms group were well controlled (ACQ7 ≤0.75) at end of treatment compared to 36% of subjects in the FF 92 micrograms group (p<0.001 95% CI 1.23, 1.82).
44 % bolnikov v skupini s flutikazonfuroatom/vilanterolom 92/22 mikrogramov je imelo na koncu zdravljenja dobro obvladano bolezen (ACQ7 ≤ 0,75); v skupini z 92 mikrogrami FF je bilo takšnih 36 % (p < 0,001, 95 % IZ od 1,23 do 1,82).